Abstracts tagged "treatment"

Abstract Number: 524 • 2019 ACR/ARP Annual Meeting
A Comparison of Upadacitinib Plus Methotrexate and Upadacitinib Plus Other CsDMARDs in Patients with Rheumatoid Arthritis: An Analysis of Two Phase 3 Studies
Joel Kremer¹, Filip Van den Bosch ², Andrea Rubbert-Roth ³, Sebastiao Radominski ⁴, Gerd Burmester ⁵, Heidi Camp ⁶, Sebastian Meerwein ⁷, Mark Howard ⁸, Yanna Song ⁹, Sheng Zhong ¹⁰ and Bernard Combe ¹¹, ¹Albany Medical College, Albany, NY, ²Ghent University Hospital, Ghent, Belgium, ³Kantonsspital St. Gallen, St Gallen, Switzerland, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵Charité—University Medicine Berlin, Berlin, Germany, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁸AbbVie Inc., North Chicago, ⁹AbbVie Inc., North Chicago, IL, USA, North Chicago, ¹⁰AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ¹¹CHU Montpellier, Montpellier University, Montpellier, France
Background/Purpose: Upadacitinib (UPA), a selective JAK1 inhibitor, has shown efficacy in patients with rheumatoid arthritis (RA) when combined with methotrexate (MTX) or other conventional synthetic…
Abstract Number: 1352 • 2019 ACR/ARP Annual Meeting
Effects of Upadacitinib on Patient-Reported Outcomes After 24 Weeks in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs: Results from SELECT-NEXT and SELECT-BEYOND Phase 3 Studies
Martin Bergman¹, Namita Tundia ², Heidi Camp ², Sebastian Meerwein ³, Casey Schlacher ², Debbie Goldschmidt ⁴, Yan Song ⁵ and Vibeke Strand ⁶, ¹Drexel University College of Medicine, Stockholm, Sweden, ²AbbVie Inc., North Chicago, IL, ³AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁴Analysis Group, Inc., New York, NY, ⁵Analysis Group, Inc., Boston, MA, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Treatment with upadacitinib (UPA), a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week 12…
Abstract Number: 1704 • 2019 ACR/ARP Annual Meeting
Efficacy of Leflunomide for Treatment of Vasculitis
NOURA MUSTAPHA ¹, Lillian Barra ², Simon Carette ³, David Cuthbertson ⁴, Nader A. Khalidi ⁵, Curry L. Koening ⁶, Carol Langford ⁷, Carol McAlear ⁸, Nataliya Milman ⁹, Larry Moreland ¹⁰, Paul Monach ¹¹, Philip Seo ¹², Ulrich Specks ¹³, Antoine Sreih ¹⁴, Steven Ytterberg ¹³, Peter Merkel ¹⁴, Christian Pagnoux¹⁵, CanVasc Canadian Vasculitis Research Network ¹⁶ and VCRC Vasculitis Clinical Research Consortium ⁸, ¹Hopital Notre Dame, Montreal, QC, Canada, ²St Joseph's health care, London, Canada, ³Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Utah Hospital, Salt Lake City, UT, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Division of Rheumatology, Philadelphia, ⁹Arthritis Centre at the Ottawa Hospital, Riverside Campus, Ottawa, Canada, ¹⁰University of Pittsburgh, PITTSBURGH, PA, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²Johns Hopkins Medicine, Baltimore, MD, ¹³Mayo Clinic College of Medicine, Rochester, MN, ¹⁴University of Pennsylvania, Philadelphia, PA, ¹⁵Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ¹⁶Mount Sinai Hospital, Vasculitis clinic, toronto, ON, Canada
Background/Purpose: Only a few small case series, case reports, and one small clinical trial suggested some benefit of leflunomide (LEF) in ANCA-associated vasculitis and other…
Abstract Number: 2756 • 2019 ACR/ARP Annual Meeting
Subcutaneous Tanezumab versus NSAID for the Treatment of Osteoarthritis: Joint Safety Events in a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study
Marc C. Hochberg¹, John Carrino ², Thomas Schnitzer ³, Ali Guermazi ⁴, David Walsh ⁵, Alexander White ⁶, Satoru Nakajo ⁷, Robert Fountaine ⁸, Anne Hickman ⁸, Glenn Pixton ⁹, Lars Viktrup ¹⁰, Mark T. Brown ⁸, Christine R. West ⁸ and Kenneth M. Verburg ⁸, ¹University of Maryland School of Medicine, Baltimore, MD, ²Hospital for Special Surgery, New York, NY, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Boston Medical Center, Boston, ⁵Sherwood Forest Hospitals NHS Foundation Trust, Nottingham, United Kingdom, ⁶Progressive Medical Research, Port Orange, FL, ⁷Nakajo Orthopaedic Clinic, Miyagi, Japan, ⁸Pfizer Inc, Groton, CT, ⁹Pfizer Inc, Morrisville, NC, ¹⁰Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Tanezumab, a monoclonal antibody inhibiting nerve growth factor (NGF), is under investigation for the treatment of chronic pain conditions. In prior osteoarthritis (OA) studies,…
Abstract Number: 531 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Gonadotropin-Releasing Hormone Antagonism in Severe Biologic Refractory Rheumatoid Arthritis
Anita Kass¹, Hans Christian Gulseth ¹ and Camilla Zettel ¹, ¹Betanien Hospital, Skien, Norway
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is unclear, and additional therapeutic approaches are needed. The improvement of RA disease activity during pregnancy, and flares during the…
Abstract Number: 1375 • 2019 ACR/ARP Annual Meeting
Patient-Reported Outcomes of Upadacitinib versus Adalimumab Use in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 26-Week Analysis of a Phase 3 Study
Roy Fleischmann¹, Martin Bergman ², Namita Tundia ³, In-Ho Song ⁴, Jessica Suboticki ⁴, Yan Song ⁵ and Vibeke Strand ⁶, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Drexel University College of Medicine, Stockholm, Sweden, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁵Analysis Group, Inc., Boston, MA, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: In patients with active rheumatoid arthritis (RA), 12-week treatment with upadacitinib (UPA) while on background MTX therapy resulted in significant and clinically meaningful improvements…
Abstract Number: 1708 • 2019 ACR/ARP Annual Meeting
Azathioprine and Glucocorticoid Combination Might Be a Good Treatment Option to Achieve Remission in Patients with IgG4-related Disease
Aydan Köken Avşar¹, Onay Gercik ², Gercek Can ³, Berrin Zengin ⁴, Sinem Burcu Kocaer ⁵, Atilla Okan Kılıç ⁶, Sadettin Uslu ⁷, Ali Karakaş ⁵, Merih Birlik ⁵, Servet Akar ⁸ and Fatos Onen ⁹, ¹Dokuz Eylul University School of Medicine, Rheumatology,, Türkiye, Izmir, Turkey, ²Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ³Dokuz Eylul University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Izmir, Turkey, ⁴Dokuz Eylul University School of Medicine, Rheumatology,, Turkey,Izmir, Izmir, Turkey, ⁵Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Turkey,Izmir, Izmir, Turkey, ⁶Dokuz Eylul University School of Medicine, Internal Medıcıne, Turkey,Izmir, Izmir, Turkey, ⁷Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Izmir, Turkey, ⁸Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ⁹Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey
Background/Purpose: IgG4-related disease is a recently recognised inflammatory disease of unkown etiology, often seen in men over the age of 50 and may affect many…
Abstract Number: 2768 • 2019 ACR/ARP Annual Meeting
Changes in B Cell Profile as a Marker of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis
Borja Hernández-Breijo¹, Israel Nieto-Gañán ², Cristina Sobrino ³, Victoria Navarro-Compán ⁴, Ana Martínez-Feito ⁵, Carlota García-Hoz ⁶, Paloma Lapuente-Suanzes ², javier Bachiller ³, Gema Bonilla ⁷, Cristina Pijoán-Moratalla ³, Garbiñe Roy ², Mónica Vázquez Díaz ³, Alejandro Balsa ⁷, Luisa María Villar ², Dora Pascual-Salcedo ¹, Eulalia Rodríguez-Martín ² and Chamaida Plasencia ⁷, ¹Immuno-Rheumatology Research Group, IdiPAZ. La Paz University Hospital, Madrid, Spain, ²Immunology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, ³Rheumatology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, ⁴University Hospital La Paz, IdiPaz, Madrid, Spain, ⁵Immuno-Rheumatology Research Group, IdiPAZ & Immunology Department. La Paz University Hospital, MADRID, Spain, ⁶Immunology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, ⁷Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain
Background/Purpose: According to the EULAR recommendations, the therapeutic objective in patients with rheumatoid arthritis (RA) should be remission. Biological therapies, as TNF inhibitors (TNFi), have…
Abstract Number: 539 • 2019 ACR/ARP Annual Meeting
A Randomized Double-Blind Study Comparing Pharmacokinetics (PK) and Pharmacodynamics (PD) of ABP 798 with Rituximab in Subjects with Moderate to Severe RA
Gerd Burmester¹, Stanley Cohen ², David Chien ³, Vincent Chow ³ and Zhiying Pan ³, ¹Charité—University Medicine Berlin, Berlin, Germany, ²Metroplex Clinical Research Center, Dallas, TX, ³Amgen, Thousand Oaks, CA
Background/Purpose: ABP 798 is being developed as a biosimilar to rituximab, a CD20-directed cytolytic antibody that is approved in the US and EU for treatment…
Abstract Number: 1376 • 2019 ACR/ARP Annual Meeting
Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials
Vibeke Strand¹, Namita Tundia ², Alan Friedman ³, Heidi Camp ², Jessica Suboticki ⁴, Debbie Goldschmidt ⁵, Catherine Fernan ⁵ and Martin Bergman ⁶, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁵Analysis Group, Inc., New York, NY, ⁶Drexel University College of Medicine, Stockholm, Sweden
Background/Purpose: Treatment with upadacitinib (UPA) monotherapy, a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week…
Abstract Number: 1763 • 2019 ACR/ARP Annual Meeting
A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus
Richard Furie¹, Eric Morand ², Ian Bruce ³, Susan Manzi ⁴, Kenneth Kalunian ⁵, Edward Vital ⁶, Theresa Lawrence-Ford ⁷, Ramesh Gupta ⁸, Falk Hiepe ⁹, Mittermayer Santiago ¹⁰, Philip Brohawn ¹¹, Anna Berglind ¹² and Raj Tummala ¹³, ¹Zucker School of Medicine at Hofstra/Northwell, New York, NY, ²Monash University, Melbourne, Victoria, Australia, ³University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁴Allegheny Health Network, Pittsburg, PA, ⁵Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ⁶University of Leeds, Leeds, United Kingdom, ⁷North Georgia Rheumatology, Lawrenceville, GA, ⁸Baptist Memorial Hospital-Memphis, Memphis, TN, ⁹Charité University Hospital Berlin, Berlin, Germany, ¹⁰Bahiana School of Medicine and Public Health, Bahia, Brazil, ¹¹AstraZeneca, Gaithersburg, MD, ¹²AstraZeneca, Gothenburg, Sweden, ¹³AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, MD
Background/Purpose: In a phase 2 study in SLE patients (pts), substantial efficacy was observed with anifrolumab, a human monoclonal antibody that binds the type I…
Abstract Number: 2771 • 2019 ACR/ARP Annual Meeting
A Phase I, Randomized, Double-blind, Placebo-controlled, Single Center, Single-dose Escalation to Investigate the Safety, Tolerability, and Pharmacodynamics of Subcutaneously Administered DEN-181 in Adult Patients with ACPA+ Rheumatoid Arthritis on Stable Methotrexate
Amee Sonigra ¹, Hendrik Nel ², Nishta Ramnoruth ², Meghna Talekar ², Joanne Tesiram ³, Frederik Stuurman ⁴, Lavinia Proctor ⁵, Helen Roberts ⁶, Robin Thurmond ⁷, Phillip Vecchio ³, Ian Gourley ⁸, Mark Rigby ⁹, Nathan Felix ¹⁰, Stephane Becart ¹¹, Kim Campbell ¹² and Ranjeny Thomas², ¹Princess Alexandra Hospital, Woolloongabba, Queensland, Australia, ²University of Queensland, Woolloongabba, Australia, ³Princess Alexandra Hospital, Woolloongabba, Australia, ⁴Centre for Human Drug Research, Leiden, Netherlands, ⁵Dendright, Woolloongabba, Australia, ⁶Dendright, Woolloongabba, Queensland, Australia, ⁷Janssen Research & Development, La Jolla, CA, ⁸Janssen Research & Development, Springhouse, ⁹Janssen Research & Development, La Jolla, ¹⁰Janssen R&D, Spring House, PA, ¹¹Janssen R&D, La Jolla, CA, ¹²Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Antigen-specific immunological tolerance strategies leverage the natural process of antigen presentation by dendritic cells (DCs) to regulate pathogenic T cells and B cells. We…
Abstract Number: 46 • 2019 ACR/ARP Annual Meeting
Key Inflammatory Biomarkers at Baseline Are Associated with Filgotinib Response at Week 12 in Rheumatoid Arthritis Patients with Inadequate Response or Intolerance to Biologic DMARDs
Peter Taylor¹, Emon Elboudwarej ², Bryan Downie ³, Rachael Hawtin ², Jinfeng Liu ² and Amer M. Mirza ², ¹University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster City, CA, ³Gilead Sciences, Inc., Foster Citty, CA
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in Phase 3 studies of active RA in patients (pts) with inadequate…
Abstract Number: 540 • 2019 ACR/ARP Annual Meeting
Comparing Real-world Retention Rates in a Matched Cohort of Rheumatoid Arthritis Patients Who Either Remained on the Etanercept Originator or Switched to a Biosimilar
Lisa Baganz¹, Anja Strangfeld ², Peter Herzer ³, Andreas Krause ⁴, Hans-Peter Tony ⁵ and Angela Zink ⁶, ¹German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Center (DRFZ), Berlin, Germany, ³Scientific Advisory Board, München, Germany, ⁴Immanuel Krankenhaus, Berlin, Germany, ⁵Department of Rheumatology/Clinical Immunology, University Hospital, Wuerzburg, Germany, Würzburg, Germany, ⁶German Rheumatism Research Centre and Charité University medicine, Berlin, Germany
Background/Purpose: In Germany, the first etanercept biosimilar was licensed in 2016. In contrast to other European countries there is no uniform recommendation for the prescription…
Abstract Number: 1379 • 2019 ACR/ARP Annual Meeting
Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study
Roy Fleischmann¹, Carlo Selmi ², Miguel Angel González-Gay ³, Hubert van Hoogstraten ⁴, Owen Hagino ⁴, Tejasweeni Rajput ⁵, Gregory St John ⁶, Frank Buttgereit ⁷ and Mark Genovese ⁸, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Humanitas Research Hospital, University of Milan, Milan, Italy, ³Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Sanofi, Bridgewater, NJ, ⁵Cytel, Mumbai, India, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁸Stanford University, Stanford, CA
Background/Purpose: EXTEND (NCT01146652) is a long-term, open-label extension (OLE) study of sarilumab for the treatment of RA. This post hoc analysis assessed changes in oral…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].